Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P

Molecular Pharmacology

Volumn 51, Issue 3, 1997, Pages 399-405

  Sumizawa, Tomoyuki ^a   Chen, Zhe Sheng ^a   Chuman, Yutaka ^a   Seto, Kiyotomo ^b   Furukawa, Tatsuhiko ^a   Haraguchi, Misako ^a   Tani, Ayako ^a   Shudo, Norimasa ^b   Akiyama, Shin Ichi ^a,c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4,6 DIMETHYL 1,3,2 DIOXAPHOSPHORINAN 2 YL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 3 PYRIDINECARBOXYLIC ACID 2 (4 BENZHYDRYL 1 PIPERAZINYL)ETHYL ESTER P OXIDE; CEPHARANTHINE; DOXORUBICIN; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ARTICLE; CELL SURVIVAL; COMPETITIVE INHIBITION; DRUG ACCUMULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0030969806     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Endicott, J. A., and V. Ling. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:137-171 (1989).
2. Gottesman, M. M., and I. Pastan. The multidrug transporter: a double-edged sword. J. Biol. Chem. 263:12163-12166 (1988).
3. Ford, J. M., and W. N. Hait. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-199 (1990).
4. Safa, A. R., C. J. Glover, J. L. Sewell, M. B. Meyers, J. L. Biedler, and R. L. Felsted. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J. Biol. Chem. 262:7884-7888 (1987).
5. Akiyama, S., M. M. Cornwell, M. Kuwano, I. Pastan, and M. M. Gottesman. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analogue. Mol. Pharmacol. 33:144-147 (1988).
6. Beck, W. T. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J. Natl. Cancer Inst. 81:1683-1685 (1989).
7. Center, M. S. Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug. Cytotechnology 12:109-125 (1993).
8. Cole, S. P. C., G. Bhardwaj, J. H. Gerlach, J. E. Mackie, C. E. Grant, K. C. Almquist, A. J. Stewart, E. U. Kurz, A. M. V. Duncan, and R. G. Deeley. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington D. C.) 258:1650-1654 (1992).
9. Sumizawa T., Y. Chuman, H. Sakamoto, K. Iemura, K. C. Almquist, R. G. Deeley, S. P. C. Cole, and S. Akiyama. Non-P-glycoprotein-mediated multidrug resistant human KB cells selected in medium containing adriamycin, cepharanthine and mezerein. Somat. Cell Mol. Genet. 20:423-435 (1994).
10. Krishnamachary, N., and M. S. Center. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53:3658-3661 (1993).
11. Zaman, G. J. R., C. H. M. Versantvoort, E. W. H. M. Eijdems, M. de Haas, A. J. Smith, H. J. Broxterman, N. H. Mulder, E. de Vries, F. Baas, and P. Borst. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 53:1747-1750 (1993).
12. Schneider, E., J. K. Horton, C.-H. Yang, M. Nakagawa, and K. H. Cowan. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 54:152-158 (1994).
13. Barrand, M. A., A. C. Heppell-Parton, K. A. Wright, P. H. Rabbitts, and P. R. A. Twentyman. Kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J. Natl. Cancer Inst. 86:110-117 (1994).
14. Zaman, G. J. R., M. J. Flens, M. R. van Leusden, M. de Haas, H. S. Mulder, J. Lankelma, H. M. Pinedo, R. J. Scheper, F. Baas, H. J. Broxterman, and P. Borst. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 91:8822-8826 (1994).
15. Jedlitschky, G., I. Leier, U. Buchholz, M. Center, and D. Keppler. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 54:4833-4836 (1994).
16. 4 and structurally related conjugates. J. Biol. Chem. 269: 27807-27810 (1994).
17. Muller, M., C. Meijer, G. J. R. Zaman, P. Borst, R. J. Scheper, N. H. Mulder, E. G. E. de Vries, and P. L. M. Jansen. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA 91:13033-13037 (1994).
18. Baker, R. M., Y. Chen, B. Richard, W. Frederricks, E. Cason, C. Karakousis, M. Center, H. K. Slocum, and Y. Rustum. Relation of multidrug resistance markers assessed by immunoblotting to clinical course for disease in adult sarcoma. Proc. Am. Assoc. Cancer Res. 34:232 (1993).
19. Thomas, G. A., M. A. Barrand, S. Stewant, P. H. Rabbitts, E. D. Williams, and P. R. Twentyman. Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumors and normal tissue as determined by in situ hybridization. Eur. J. Cancer 30A:1705-1709 (1994).
20. Schneider, E., K. H. Cowan, H. Bader, S. Toomey, G. W. N. Schwartz, J. E. Karp, and P. J. Burke. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:185-193 (1995).
21. Cole, S. P. C. The Merck Frosst Award: Multidrug resistance in small cell lung cancer. Can. J. Physiol. Pharmacol. 70:313-329 (1992).
22. Versantvoort, C. H. M., H. J. Broxterman, T. Bagrij, and P. R. Twentyman. Reversal of drug resistance in MRP overexpressing multidrug resistant human lung tumor cells (Abstract). Anti-Cancer Drugs 5:30 (1994).
23. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 208:345-352 (1995).
24. Shudo, N., T. Mizoguchi, T. Kiyosue, M. Arita, A. Yoshimura, K. Seto, R. Sakoda, and S. Akiyama. Two pyridine analogs with more effective ability to reverse multidrug resistance and lower calcium channel blocking activity than their dihydropyridine counterparts. Cancer Res. 50:3055-3061 (1990).
25. Tsuruo, T., H. Iida, S. Tsukagoshi, and Y. Sakurai. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41: 1967-1972 (1981).
26. Shiraishi, N., S. Akiyama, M. Nakagawa, M. Kobayashi, and M. Kuwano. Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Res. 47:2413-2416 (1987).
27. Akiyama, A., A. Fojo, J. A. Hanover, I. Pastan, and M. M. Gottesman. Isolation and genetic characterization of human KB cells resistant to multiple drugs. Somat. Cell Genet. 11:117-126 (1985).
28. Carmichael, J., W. G. DeGraff, A. F. Gazdar, J. D. Minna, and J. B. Mitchell. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936-942 (1987).
29. Kartner, N., D. Evernden-Porelle, G. Bradley, and V. Ling. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature (Lond.) 316:820-823 (1985).
30. Takano, H., K. Kohno, M. Ono, Y. Uchida, and M. Kuwano. Increased phosphorylation of DNA Topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 51:3951-3957 (1991).
31. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.) 227:680-685 (1970).
32. Towbin, H., T. Staehelin, and J. Gordon. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-4354 (1979).
33. Kyhse-Andersen, J. Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J. Biochem. Biophys. Methods 10:203-209 (1984).
34. Bjerrum, O. J., and C. Schafer-Nielsen. Buffer systems and transfer parameters for semidry electroblotting with a horizontal apparatus, in Analytical Electrophoresis (M. J. Dunn, ed.). Verlag Chemie, Weinheim, 315-327 (1986).
35. Krishnamachary, N., and M. S. Center. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53: 3658-3661 (1993).
36. Lever, J. E. Active amino acid transport in plasma membrane vesicles from Simian virus 40-transformed mouse fibroblasts. J. Biol. Chem. 252: 1990-197 (1977).
37. Bradford, M. A. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72:248-254 (1976).
38. 2+-dependent cardiac transport system for glutathione S-conjugates. J. Biol. Chem. 264:17343-17348 (1989).
39. Ishikawa, T., and F. Ali-Osman. Glutathione-associated cisdiamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem. 268:20116-20125 (1993).
40. Niwa, K., K. Yamada, T. Furukawa, N. Shudo, K. Seto, T. Matsumoto, S. Takao, S. Akiyama, and H. Shimazu. Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1-(2- morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate, on reversing in vivo resistance of tumor cells to adriamycin. Cancer Res. 52:3655-3660 (1992).
41. Cole, S. P. C., E. R. Chanda, F. P. Dicke, J. H. Gerlach, and S. E. L. Mirski. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug DNA damage and reduced levels of topoisomerase II. Cancer Res. 51:3345-3352 (1991).
42. Doyle, L. A., D. D. Ross, J. V. Ordonez, W. Yang, Y. Gao, Y. Tong, C. P. Belani, and J. C. Gutheli. An etoposide-resistant small cell lung cancer subline overexpresses the MRP gene. Proc. Am. Assoc. Cancer Res. 35:467a (1994).
43. McGrath, T., C. Latoud, S. T. Arnold, A. R. Safa, R. J. Felsted, and M. S. Center. Mechanisms of multidrug resistance in HL60 cells: analysis of resistance associated membrane protein and levels of mdr gene expression. Biochem. Pharmacol. 38:3611-3619 (1989).
44. Zijlstra, J. G., E. G. C. deVrise, and N. H. Mulder. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 47:1780-1784 (1987).
45. Slovak, M. L., G. A. Hoeltge, W. S. Dalton, and J. M. Trent. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 48:2793-2797 (1988).
46. Ishikawa, T., M. Muller, C. Klunemann, T. Schaub, and D. Keppler. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane: role of the ATP-dependent transport system for glutathione S-conjugates. J. Biol. Chem. 265:19279-19286 (1990).
47. Ishikawa, T., K. Akimaru, M. T. Kuo, W. Priebe, and M. Suzuki. How does the MRP/GS-X pump export doxorubicin? J. Natl. Cancer Inst. 87:1639-1640 (1995).
48. Versantvoort, C. H. M., H. J. Broxterman, J. Lankelma, N. Feller, and H. M. Pinedo. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol. 48:1129-1136 (1994).